Seema Sheoran
Stock Analyst at Rodman & Renshaw
(2.80)
# 2,878
Out of 4,673 analysts
6
Total ratings
33.3%
Success rate
21.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Seema Sheoran
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ELDN Eledon Pharmaceuticals | Initiated Coverage: Buy | $12 | $3.42 | +250.88% | 1 | Jul 21, 2026 | |
| NGNE Neurogene | Initiated Coverage: Buy | $70 | $39.95 | +75.22% | 1 | Jun 3, 2026 | |
| AVXL Anavex Life Sciences | Initiated Coverage: Buy | $20 | $3.11 | +544.12% | 1 | May 4, 2026 | |
| CAMP Camp4 Therapeutics | Initiated Coverage: Buy | $7 | $4.38 | +59.82% | 1 | Apr 14, 2026 | |
| SABS SAB Biotherapeutics | Initiated Coverage: Buy | $13 | $3.63 | +258.13% | 1 | Apr 2, 2026 | |
| SGMT Sagimet Biosciences | Initiated Coverage: Buy | $28 | $10.22 | +173.97% | 1 | Mar 26, 2026 |
Eledon Pharmaceuticals
Jul 21, 2026
Initiated Coverage: Buy
Price Target: $12
Current: $3.42
Upside: +250.88%
Neurogene
Jun 3, 2026
Initiated Coverage: Buy
Price Target: $70
Current: $39.95
Upside: +75.22%
Anavex Life Sciences
May 4, 2026
Initiated Coverage: Buy
Price Target: $20
Current: $3.11
Upside: +544.12%
Camp4 Therapeutics
Apr 14, 2026
Initiated Coverage: Buy
Price Target: $7
Current: $4.38
Upside: +59.82%
SAB Biotherapeutics
Apr 2, 2026
Initiated Coverage: Buy
Price Target: $13
Current: $3.63
Upside: +258.13%
Sagimet Biosciences
Mar 26, 2026
Initiated Coverage: Buy
Price Target: $28
Current: $10.22
Upside: +173.97%